ACA
REGN icon

Atlas Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Atlas Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.99M Hold
7,758
– – 0.69% 40
2025
Q4 		$5.99M Buy
+7,758
New +$5.27M 0.67% 41
2025
Q2 		$4.07M Sell
7,758
-700
-8% -$391K 0.5% 49
2025
Q1 		$5.36M Sell
8,458
-8
-0.1% -$5.5K 0.67% 42
2024
Q4 		$6.03M Buy
8,466
+8,318
+5,620% +$6.98M 0.77% 37
2024
Q3 		$156K Sell
148
-8,334
-98% -$9.27M 0.02% 416
2024
Q2 		$8.91M Buy
8,482
+8,331
+5,517% +$8.08M 1.16% 21
2024
Q1 		$145K Sell
151
-8,334
-98% -$7.92M 0.02% 424
2023
Q4 		$7.45M Hold
8,485
– – 1.08% 22
2023
Q3 		$6.98M Hold
8,485
– – 1.15% 21
2023
Q2 		$6.1M Sell
8,485
-2
-0% -$1.54K 0.92% 25
2023
Q1 		$6.97M Hold
8,487
– – 1.1% 23
2022
Q4 		$6.12M Hold
8,487
– – 1.03% 24
2022
Q3 		$5.85M Sell
8,487
-15
-0.2% -$9.44K 1.06% 21
2022
Q2 		$5.03M Buy
8,502
+20
+0.2% +$13K 0.85% 26
2022
Q1 		$5.92M Buy
8,482
+9
+0.1% +$5.69K 0.92% 29
2021
Q4 		$5.35M Hold
8,473
– – 0.8% 31
2021
Q3 		$5.13M Hold
8,473
– – 0.82% 30
2021
Q2 		$4.73M Hold
8,473
– – 0.79% 29
2021
Q1 		$4.01M Sell
8,473
-296
-3% -$144K 0.78% 29
2020
Q4 		$4.24M Sell
8,769
-340
-4% -$184K 0.89% 27
2020
Q3 		$5.1M Buy
9,109
+530
+6% +$321K 1.21% 16
2020
Q2 		$5.35M Buy
8,579
+121
+1% +$68.7K 1.26% 12
2020
Q1 		$4.13M Hold
8,458
– – 1.23% 14
2019
Q4 		$3.18M Hold
8,458
– – 0.79% 24
2019
Q3 		$2.35M Hold
8,458
– – 0.71% 23
2019
Q2 		$2.65M Hold
8,458
– – 0.87% 16
2019
Q1 		$3.47M Hold
8,458
– – 1.25% 11
2018
Q4 		$3.16M Hold
8,458
– – 1.27% 10
2018
Q3 		$3.41M Hold
8,458
– – 1.14% 15
2018
Q2 		$3.09M Hold
8,458
– – 1.1% 14
2018
Q1 		$2.91M Buy
+8,458
New +$2.94M 0.89% 15

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Atlas Capital Advisors's REGN Position: Q1 2026 in Review

Atlas Capital Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 7,758 shares worth $5.99M. The position accounts for 0.69% of the portfolio, ranked #40.

Atlas Capital Advisors first reported a position in REGN in Q1 2018 and has held it in 32 quarters since. The position peaked at $8.91M in Q2 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Atlas Capital Advisors held 7,758 shares of Regeneron Pharmaceuticals worth $5.99M as of Q1 2026.
  • Atlas Capital Advisors left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.69% of Atlas Capital Advisors's portfolio in Q1 2026, its #40 holding.
  • Atlas Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2018 and has held it in 32 quarters since.
  • Atlas Capital Advisors's Regeneron Pharmaceuticals position peaked at $8.91M in Q2 2024.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Atlas Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.